Physician profile
Priti Kothari
NPI 1306936745
$6,870.23
in general payments reported to CMS, 2019-2025
31 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 91% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $202 · 2021: $103 · 2022: $558 · 2023: $1,749 · 2024: $1,496 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,786.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $1,612.21 | 2022-2025 | Azstarys |
| Abbvie INC. | $1,137.52 | 2021-2025 | |
| Tris Pharma INC | $741.28 | 2019-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $475.17 | 2022-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $299.01 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Allergan, INC. | $257.95 | 2019-2020 | |
| Lilly USA, LLC | $249.99 | 2023-2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $234.58 | 2024 | Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $211.45 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $171.61 | 2025 | Jornay Pm |
| Shire North American Group INC | $148.14 | 2019 | |
| Lundbeck LLC | $142.22 | 2019-2024 | Rexulti |
| Glaxosmithkline, LLC. | $128.13 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2024 | Tezspire |
| Amgen INC. | $124.99 | 2024 | Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $122.61 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $101.52 | 2019-2024 | Spravato |
| Genzyme Corporation | $98.33 | 2025 | |
| Vertical Pharmaceuticals, LLC | $84.38 | 2019 | |
| Endo Pharmaceuticals INC. | $74.96 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $66.23 | 2024-2025 | Rexulti |
| Adlon Therapeutics L.P. | $57.21 | 2019 | |
| Arbor Pharmaceuticals, INC. | $31.78 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.28 | 2025 | Caplyta |
| Acell, INC. | $26.72 | 2019 | |
| Noven Therapeutics, LLC | $22.13 | 2024 | Secuado, Xelstrym |
| Validus Pharmaceuticals LLC | $20.61 | 2025 | Equetro |
| Sunovion Pharmaceuticals INC. | $20.57 | 2020 | |
| Covidien LP | $20.44 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.92 | 2025 | Fanapt |
| Jazz Pharmaceuticals INC. | $16.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priti Kothari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.